Prostate cancer (PC) is a major health issue. Progression to castration resistant disease is highly lethal due to treatment resistance. We found that, PML, a key suppressor of PC, is promoted for degradation by the enzyme, E6AP. Increased E6AP expression is associated with a loss of PML in PC. Here we propose to test the anti-tumour efficacy of blocking E6AP to restore the ability of PML to selectively kill PC cells. If successful, this will form a novel treatment for localized and advanced PC.
Prof Ygal Haupt, Dr Shahneen Sandhu
Cancer Council Research Grant
Sr Peter MacCallum Department of Oncology, The University of Melbourne
$100,000 per annum